Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro.

Rahaman KA, Muresan AR, Min H, Son J, Han HS, Kang MJ, Kwon OS

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences7 Feb 2024Cited by 4 (Europe PMC)

PMID38382158DOI10.1016/j.jchromb.2024.124033PepBankPUB-38382158

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Pharmacokinetics
In rats treated with TB‑500, Ac-LK was the primary metabolite and had the highest concentration at 0-6 h intervals.
In plain wordsIn rats given TB‑500, the breakdown product Ac-LK was the main one and was highest in the first 6 hours.
Peptide
TB-500
Outcome
Not applicableAc-LK urine concentration (0-6 h)
Study
ratn: not reported in source
urine of rats treated with TB-500
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated
Measurements
Time interval of highest Ac-LK concentration
0 to 6 h
rat urine
Source sentences
Summary
The study found that Ac-LK was the primary metabolite with the highest concentration in rats at 0-6 h intervals.
1 context sentence(design, population, supporting numbers)
Summary · context
The metabolism of TB-500 was investigated in human serum, various in-vitro enzyme systems, and urine samples from rats treated with TB-500, and their biological activities measured by cytotoxicity and wound healing experiments were also evaluated in fibroblasts.
Report a problemFND-3838215802
02AnimalAnimal study (in vivo)Pharmacokinetics
In rats treated with TB‑500, the metabolite Ac-LKK was a long-term metabolite detected up to 72 hr.
In plain wordsIn rats given TB‑500, the breakdown product Ac-LKK could be found for up to 72 hours.
Peptide
TB-500
Outcome
Not applicableAc-LKK detection time
Study
ratn: not reported in source
urine of rats treated with TB-500
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated
Measurements
Detection time of Ac-LKK
≤ 72 hr
rat urine
Source sentences
Summary
Also, the metabolite Ac-LKK was a long-term metabolite of TB-500 detected up to 72 hr.
1 context sentence(design, population, supporting numbers)
Summary · context
The metabolism of TB-500 was investigated in human serum, various in-vitro enzyme systems, and urine samples from rats treated with TB-500, and their biological activities measured by cytotoxicity and wound healing experiments were also evaluated in fibroblasts.
Report a problemFND-3838215803
03LabIn vitro (cells)Safety outcome
In fibroblasts, no cytotoxicity of TB‑500 or its metabolites was found.
In plain wordsIn lab-grown fibroblast cells, neither TB‑500 nor its breakdown products were toxic to the cells.
Peptide
TB-500
Outcome
No significant changeCytotoxicity of TB-500 and metabolites
Study
n: not reported in source
fibroblasts
Outcome group
Adverse events · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
No cytotoxicity of the parent and its metabolites was found.
1 context sentence(design, population, supporting numbers)
Summary · context
The metabolism of TB-500 was investigated in human serum, various in-vitro enzyme systems, and urine samples from rats treated with TB-500, and their biological activities measured by cytotoxicity and wound healing experiments were also evaluated in fibroblasts.
Report a problemFND-3838215804
04LabIn vitro (cells)Efficacy outcome
In fibroblast wound healing experiments, parent TB‑500 showed no significant wound healing activity compared with control; only the metabolite Ac-LKKTE did.
In plain wordsIn lab-grown fibroblast cells, TB‑500 itself did not speed wound closing compared with control; only one breakdown product, Ac-LKKTE, did.
Peptide
TB-500
Outcome
No significant changeWound healing activity of parent TB-500
Study
n: not reported in source
fibroblasts
Comparator
Control
Outcome group
Wound healing · Skin and wound
Studied dose
Dose not stated
Source sentences
Summary
Ac-LKKTE only showed a significant wound healing activity compared to the control.
2 context sentences(design, population, supporting numbers)
Summary · context
Our results also suggest that the previously reported wound-healing activity of TB-500 in literature may be due to its metabolite Ac-LKKTE rather than the parent form.
Summary · context
The metabolism of TB-500 was investigated in human serum, various in-vitro enzyme systems, and urine samples from rats treated with TB-500, and their biological activities measured by cytotoxicity and wound healing experiments were also evaluated in fibroblasts.
Report a problemFND-3838215805

Studies that did not test the peptide alone1

In this study, TB-500 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking TB-500.

05LabNot a test of TB-500 aloneIn vitro (cell-free)Other
A simultaneous analytical method for TB‑500 and its metabolites was developed and validated.
In plain wordsIn lab work, the researchers built and checked a test that measures TB‑500 and its breakdown products together.
Peptide
TB-500
Outcome
Not applicableUHPLC-Orbitrap MS/MS method for TB-500 and metabolites
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
The simultaneous analytical method for TB-500 and its metabolites was developed and validated.
1 context sentence(design, population, supporting numbers)
Summary · context
The metabolism of TB-500 was investigated in human serum, various in-vitro enzyme systems, and urine samples from rats treated with TB-500, and their biological activities measured by cytotoxicity and wound healing experiments were also evaluated in fibroblasts.
In this study, TB-500 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking TB-500.
Report a problemFND-3838215801

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 5 to 29Current
28 Oct 2026, 02:04 UTC
The same notice was added 25 times, first on 13 Oct 2026, 01:52 UTC. The status did not change between them.
Study results updated
Version 4
12 Oct 2026, 18:17 UTC
Study data updated · source update from Europe PMC
Version 3
9 Oct 2026, 18:17 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.